Argentina Risk Management Report: ISO 14971 Alignment and Review Consistencies
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
Argentine submissions must include a risk management report conforming to ISO 14971. Its position in the review is not that of a standalone document, but that of one link in a chain of evidence that corroborates the technical report: the technical report states that the product is safe and effective, and the risk management report explains how that safety is systematically assured. The two documents are read together, and any gap between them weakens both.
The review focuses on 3 consistencies: the risk acceptability conclusions must be consistent with the performance claims in the technical report; the risk control measures must be consistent with the design and process descriptions; and the disclosure of residual risks must be consistent with the warnings and precautions in the instructions for use. These three checks are where most deficiency letters originate, because they are the easiest points for an examiner to verify across documents.
The emphasis on consistency also tells applicants where to invest. A risk management report that is methodologically elaborate but inconsistent with the rest of the file will generate more findings than a simpler report that aligns perfectly with the technical documentation and the IFU. The review reward therefore goes to alignment work, which is cheap, rather than to methodological refinement, which is expensive and rarely what the deficiency letter is about.
2. Legal basis
| Regulatory instrument | Number | Publication date | Relevant provisions |
|---|---|---|---|
| MERCOSUR technical regulation for medical device registration | GMC/RES 25/21 | October 13, 2021 | Annex V (technical report); Part III (technical documentation) |
| MERCOSUR essential requirements | GMC/RES 72/98 | 1998 | Essential requirements for safety and effectiveness (including risk-related items) |
| Domestic implementing instrument | Disposición ANMAT 64/2025 | Published in the Official Gazette on January 13, 2025 | Provisions on technical documentation requirements |
| Good technovigilance practices | Disposición ANMAT 8194/2023 | Published October 3, 2023, effective October 4, 2023 | Provisions linking risk management and vigilance |
The framework connects the pre-market and post-market halves of risk management. GMC/RES 25/21 and GMC/RES 72/98 require the risk evidence inside the dossier, Disposición ANMAT 64/2025 confirms those documentation duties domestically, and Disposición ANMAT 8194/2023 extends the same risk logic into the post-market phase by obliging holders to keep the risk documentation current as vigilance data accumulates.
This continuity has a practical consequence for how the file should be built in the first place. If the submission-phase risk report is written as a closed, one-time artifact, updating it later means reworking its structure; if it is written from the start as a maintained document, with dated revisions and a defined owner, the post-market updates become routine entries rather than reconstruction projects. The difference shows up years later, at the first renewal or the first significant vigilance event.
3. Expert insights
Insight 1: the risk management report is a living document, connected to post-market obligations. Disposición 8194/2023 requires registration holders to continuously monitor product performance in the Argentine market and to update the risk management documentation as new information emerges. This means the risk documentation prepared for the submission must be maintained after the certificate is granted, and vigilance data must flow back into the risk file. A risk report frozen at the submission date will fall out of step with the holder’s own post-market record.
Insight 2: the three consistencies are the real checkpoints of the review. Many deficiency letters are issued not because the risk management report is defective in itself, but because it contradicts the technical report or the instructions for use, for example when a residual risk appears in the risk file without a corresponding warning in the IFU, or when the technical report claims a performance level that the risk file classifies as an unacceptable failure mode. Aligning the three documents before submission removes an entire class of findings.
Insight 3: pay attention to the ISO 14971 version and the transition period. The submission should use the current valid version, and the file should state the version relied on and the risk acceptability criteria applied, so that the reviewer can follow the assessment directly. Stating the criteria explicitly also disciplines the internal team, since acceptability judgments made ad hoc during development tend to be inconsistent when challenged in review.
4. Practical recommendations
- Build a three-way cross-check table covering the technical report, the risk file and the IFU. Verify item by item that the performance claims, the risk control measures and the residual risk disclosures agree across all three documents, and resolve every mismatch before submission rather than in a deficiency response.
- State the version and the criteria in the risk file. Declare the ISO 14971 version used, the source of the risk acceptability criteria and the basis of each judgment, so the assessment is auditable without inference.
- Establish a post-grant update mechanism for the risk file. Feed vigilance data, complaint data and trend analysis results back into the risk management documentation at defined intervals, and keep records of each update to demonstrate a functioning loop.
- Reassess risks at every major change. Changes to design, materials, processes or the manufacturing site must trigger a fresh review of the risk file, together with an assessment of whether the change itself is a notifiable change to the registration.
5. Verification checklist
- □ Risk management report conforms to ISO 14971 and states the version used
- □ Risk acceptability criteria defined and their source explained
- □ Three-way cross-check table completed for the technical report, the risk file and the IFU
- □ Risk control measures consistent with the design and process descriptions in the technical report
- □ Residual risk disclosures consistent with the IFU warnings
- □ Post-grant update and vigilance data feedback mechanism for the risk file in place
Regulatory information verified as of October 29, 2026.
In Argentina, GRZAN operates a wholly owned subsidiary that can serve as the registration holder and importer of record for foreign manufacturers, directly handling classification assessment, pathway selection, building the GMP and CFS documentation chain, Spanish-language localization of technical documentation and labeling, HELENA submissions and responses to deficiency letters, as well as BONITA import notifications, operation of the ARGOS vigilance system, change maintenance and planning for the 5-year renewal. For support with registration dossiers and conformity documentation for the Argentine market, contact the GRZAN regulatory team at info@grzanglobal.com.
The GRZAN regulatory team consists of professionals with many years of hands-on experience in international registrations, tracks the activity of regulatory authorities across markets on an ongoing basis, and applies a writing standard of conclusions first, traceable sources and verifiable figures to everything it publishes. For a market access plan tailored to a specific product in Argentina or the wider MERCOSUR region, the GRZAN regulatory team welcomes your enquiry at info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us